Zorevunersen
RNA / oligonucleotide
Also known as STK-001
Evidence outlook · registrational
Dravet Syndrome: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2027-03.
Company guidance: topline data expected Q3 2027 (Stoke Therapeutics, Inc., 3 Aug 2026). “Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027–” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06872125 NCT06872125 · Dravet Syndrome Registry: NCT06872125 | 3 | Measurement of Seizure Change (Week 28) 2027-03 | In progress: results expected 1 Mar 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other SCN1A mRNA drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Dravet Syndrome: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zorevunersen: this drug | Phase 3 | RNA / oligonucleotide | SCN1A mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Clemizole (EPX-100) | Phase 3 | Small molecule | Histamine H1 receptor, Serotonin receptors (5-HT) | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (Kanbis) | Phase 2(overall) | Small molecule | cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| Huperzine A (SPN-817) | Phase 2(overall) | Small molecule | Acetylcholinesterase | not yet graded | No reviewed efficacy summary in this indication | |
| ION337 | Phase 1/2(overall) | RNA / oligonucleotide | SCN1A mRNA | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zorevunersen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.